BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10359050)

  • 1. Radioimmunotherapy for liver micrometastases in mice: pharmacokinetics, dose estimation, and long-term effect.
    Saga T; Sakahara H; Nakamoto Y; Sato N; Zhao S; Iida Y; Kuroki M; Endo K; Konishi J
    Jpn J Cancer Res; 1999 Mar; 90(3):342-8. PubMed ID: 10359050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.
    Sato N; Saga T; Sakahara H; Yao Z; Nakamoto Y; Zhang M; Kuroki M; Matsuoka Y; Iida Y; Konishi J
    J Nucl Med; 1999 Apr; 40(4):685-92. PubMed ID: 10210230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
    Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
    Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinoembryonic antigen expression, antibody localisation and immunophotodetection of human colon cancer liver metastases in nude mice: a model for radioimmunotherapy.
    Vogel CA; Galmiche MC; Westermann P; Sun LQ; Pèlegrin A; Folli S; Bischof Delaloye A; Slosman DO; Mach JP; Buchegger F
    Int J Cancer; 1996 Jul; 67(2):294-302. PubMed ID: 8760602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avidin chase can reduce myelotoxicity associated with radioimmunotherapy of experimental liver micrometastases in mice.
    Sato N; Saga T; Sakahara H; Nakamoto Y; Zhao S; Kuroki M; Iida Y; Endo K; Konishi J
    Jpn J Cancer Res; 2000 Jun; 91(6):622-8. PubMed ID: 10874215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.
    Stein R; Juweid M; Mattes MJ; Goldenberg DM
    Cancer Biother Radiopharm; 1999 Feb; 14(1):37-47. PubMed ID: 10850286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy of carcinoma of colon with [131I]-labeled recombinant chimeric monoclonal antibodies to carcinoembryonic antigen.
    Lu QJ; Bian GX; Chen YY; Zhang M; Guo SM; Wen LQ
    Acta Pharmacol Sin; 2005 Oct; 26(10):1259-64. PubMed ID: 16174444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments.
    Buchegger F; Pfister C; Fournier K; Prevel F; Schreyer M; Carrel S; Mach JP
    J Clin Invest; 1989 May; 83(5):1449-56. PubMed ID: 2708519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunotherapy of human colon carcinoma by 131I-labelled monoclonal anti-CEA antibodies in a nude mouse model.
    Buchegger F; Vacca A; Carrel S; Schreyer M; Mach JP
    Int J Cancer; 1988 Jan; 41(1):127-34. PubMed ID: 3335416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts.
    Buchsbaum DJ; ten Haken RK; Heidorn DB; Lawrence TS; Glatfelter AA; Terry VH; Guilbault DM; Steplewski Z; Lichter AS
    Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1033-41. PubMed ID: 2347713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
    Kraeber-Bodéré F; Faibre-Chauvet A; Saï-Maurel C; Gautherot E; Fiche M; Campion L; Le Boterff J; Barbet J; Chatal JF; Thédrez P
    J Nucl Med; 1999 Jan; 40(1):198-204. PubMed ID: 9935077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen.
    Sharkey RM; Pykett MJ; Siegel JA; Alger EA; Primus FJ; Goldenberg DM
    Cancer Res; 1987 Nov; 47(21):5672-7. PubMed ID: 3664474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer.
    Ychou M; Azria D; Menkarios C; Faurous P; Quenet F; Saint-Aubert B; Rouanet P; Pèlegrin M; Bascoul-Mollevi C; Guerreau D; Saccavini JC; Mach JP; Artus JC; Pèlegrin A
    Clin Cancer Res; 2008 Jun; 14(11):3487-93. PubMed ID: 18519781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant 131I-anti-CEA-antibody radioimmunotherapy inhibits the development of experimental colonic carcinoma liver metastases.
    Mahteme H; Lövqvist A; Graf W; Lundqvist H; Carlsson J; Sundin A
    Anticancer Res; 1998; 18(2A):843-8. PubMed ID: 9615730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody.
    Stein R; Govindan SV; Hayes M; Griffiths GL; Hansen HJ; Horak ID; Goldenberg DM
    Clin Cancer Res; 2005 Apr; 11(7):2727-34. PubMed ID: 15814655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
    Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
    Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody.
    Gautherot E; Kraeber-Bodéré F; Daniel L; Fiche M; Rouvier E; Saï-Maurel C; Thedrez P; Chatal JF; Barbet J
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3177s-3182s. PubMed ID: 10541361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
    Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
    J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.